A Phase II Trial of MK-3475 (Pembrolizumab) and Interferon Gamma 1-b Combination Immunotherapy in Patients With Previously Treated Mycosis Fungoides and Sezary Syndrome
Phase of Trial: Phase II
Latest Information Update: 18 Aug 2018
At a glance
- Drugs Interferon gamma-1b (Primary) ; Pembrolizumab (Primary)
- Indications Mycosis fungoides; Sezary syndrome
- Focus Therapeutic Use
- 01 Jun 2018 Planned End Date changed from 1 May 2018 to 1 May 2020.
- 01 Jun 2018 Planned primary completion date changed from 1 May 2018 to 1 May 2020.
- 01 Jun 2018 Planned number of patients changed from 36 to 30.